| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1011304979 |
| P356 | DOI | 10.1186/2051-1426-1-11 |
| P932 | PMC publication ID | 4019909 |
| P698 | PubMed publication ID | 24829748 |
| P5875 | ResearchGate publication ID | 257885157 |
| P50 | author | Hans-Georg Rammensee | Q1577018 |
| Nicholas P. Restifo | Q7026017 | ||
| Francesco Marincola | Q107723823 | ||
| P2093 | author name string | Ena Wang | |
| Willem W Overwijk | |||
| P2860 | cites work | Epitope landscape in breast and colorectal cancer | Q51894674 |
| Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival | Q56986695 | ||
| The response of autologous T cells to a human melanoma is dominated by mutated neoantigens | Q24535034 | ||
| Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma | Q28189622 | ||
| Adoptive immunotherapy for cancer: harnessing the T cell response | Q28262548 | ||
| A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma | Q28296086 | ||
| Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells | Q30442808 | ||
| Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells | Q30621114 | ||
| A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma | Q34021153 | ||
| Soluble plasma HLA peptidome as a potential source for cancer biomarkers | Q34279102 | ||
| Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion | Q36745336 | ||
| Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting | Q37418530 | ||
| The cancer antigenome | Q38069075 | ||
| Exploiting the mutanome for tumor vaccination. | Q39413641 | ||
| In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census | Q41771171 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | immunotherapy | Q1427096 |
| mutational analysis | Q1955810 | ||
| P304 | page(s) | 11 | |
| P577 | publication date | 2013-07-29 | |
| P1433 | published in | Journal for Immunotherapy of Cancer | Q27725163 |
| P1476 | title | Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors | |
| P478 | volume | 1 |
| Q63804628 | A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients |
| Q59352404 | A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs) |
| Q38284692 | Antigen-specific vaccines for cancer treatment |
| Q39130420 | Applications of Immunogenomics to Cancer |
| Q26770668 | Cancer prevention: state of the art and future prospects |
| Q27024438 | Cancer vaccines |
| Q39005199 | Combinatorial immunotherapy for melanoma |
| Q48160317 | Current challenges for cancer vaccine adjuvant development. |
| Q47617121 | Dramatic response to nivolumab in xeroderma pigmentosum skin tumor. |
| Q37516937 | Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model |
| Q46721978 | Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. |
| Q37269005 | Genomic landscape of DNA repair genes in cancer |
| Q38926293 | High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma |
| Q28078539 | Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? |
| Q52607637 | Innovative array-based assay for omics pattern in melanoma |
| Q30002365 | Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation |
| Q36716660 | Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. |
| Q34619293 | Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy |
| Q52746279 | Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer. |
| Q38646138 | Novel Treatments in Development for Melanoma. |
| Q36173439 | Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. |
| Q34359984 | Peptides and peptidomimetics as immunomodulators |
| Q26764984 | Precision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality? |
| Q37742635 | Precision medicine driven by cancer systems biology |
| Q26782580 | Systems Biology Approach for Cancer Vaccine Development and Evaluation |
| Q54217605 | Targeting Head and Neck Cancer by Vaccination |
| Q57799084 | The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match |
| Q34483345 | Trial Watch: Peptide-based anticancer vaccines |
| Q37320131 | Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. |
| Q38246769 | mRNA-based dendritic cell vaccines. |
Search more.